Phase 1, Double Blind, Sponsor Open, Randomized, Placebo Controlled, Dose Escalation, Parallel Group Study To Investigate The Safety, Tolerability And Pharmacokinetics Of Repeat Doses Of PF-06412562 In Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 28 May 2014
At a glance
- Drugs PF 6412562 (Primary)
- Indications Cognition disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 27 Mar 2014 Status changed from recruiting to completed, as per ClinicalTrials.gov record.
- 01 Nov 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 15 Oct 2013 New trial record